Launched enzyme back. Let's see. Just about a year ago, cut out in stealth.

2018 really came to market now about 21 customers paying, call it 50,000 bucks in terms of ACV each.

That's about, you know, about a million bucks in a run rate today.

Up from just $1,500 a month a year ago. So healthy growth there.

Obviously small numbers, but still healthy growth.

Hoping to get closer. They're flooring with breakeven right now. They raise about $3 million all in a safe, hoping to do a price down here soon to grow their enterprise sales force.

Currently, eight people really tech heavy in Sanfran and other remote locations.

No churn yet.

Too early to talk about KAC and things like payback period,

but they are obviously looking to scale.

Jared, thank you, again, so much for taking.

By the way, I should also put in the summary, again, helping medical device companies get to market and get their products to market faster and then also stay compliant.

Hello, everyone. My guest today is Jared Seahoffer. He is the CEO and co-founder of Enzyme,

a software company that automates life science regulatory approval and compliance. He's a 12-year

veteran of the medical device and biopharma industries having worked or consulted at organizations ranging from Amgen, Abbott,

and Metronic to Seed Sage startups. Jared, are you ready to take us to the top?

Let's do it. All right, complex space here. Help us understand what you do and how you make money.

Sure thing. So if you are a company making life science technology, this is going to be drug,

medical device, diagnostic, something like

an MRI, a pill. Anything that is used in the practice of medicine besides a doctor or a nurse

kind of rendering professional judgment, there's a complex regulatory pathway you have to go through,

and it's different for every country. In the United States, that's the FDA. Most people are familiar with that,

...